Last reviewed · How we verify

Ketofol(ketamine+propofol)

Post Graduate Institute of Medical Education and Research, Chandigarh · FDA-approved active Small molecule

Ketofol is a fixed-dose combination of ketamine (NMDA receptor antagonist) and propofol (GABA-A agonist) that produces rapid sedation and anesthesia with preserved airway reflexes and hemodynamic stability.

Ketofol is a fixed-dose combination of ketamine (NMDA receptor antagonist) and propofol (GABA-A agonist) that produces rapid sedation and anesthesia with preserved airway reflexes and hemodynamic stability. Used for Induction and maintenance of general anesthesia, Procedural sedation.

At a glance

Generic nameKetofol(ketamine+propofol)
SponsorPost Graduate Institute of Medical Education and Research, Chandigarh
Drug classFixed-dose combination anesthetic
TargetNMDA receptor (ketamine); GABA-A receptor (propofol)
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Ketamine blocks N-methyl-D-aspartate (NMDA) receptors to provide dissociative anesthesia and analgesia while maintaining spontaneous breathing and airway tone. Propofol enhances GABAergic inhibition in the central nervous system for rapid hypnosis. The combination leverages ketamine's hemodynamic stability and analgesic properties with propofol's rapid onset and smooth induction, while potentially reducing the dose-related adverse effects of either agent alone.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: